|
summary: This preliminary study looked at the clinical and MRI effects of daclizumab, a monoclonal antibody, in a small group of people with active relapsing MS despite interferon. Results were encouraging, showing a reduction in MRI active lesions and an improvement in clinical scores. Larger studies are now needed.
authors: Rose JW, Burns JB, Bjorklund J, Klein J, Watt HE, Carlson NG.
source: Neurology. 2007 Aug 21;69(8):785-9.
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
Antigen
Interferon
Lesion
Magnetic Resonance Imaging (MRI)
Multiple sclerosis
Plaque
Sclerosis
|
